Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_assertion type Assertion NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_head.
- NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_assertion wasGeneratedBy ECO_0000203 NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_provenance.
- NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_assertion wasDerivedFrom befree-20150227 NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_provenance.
- NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_assertion SIO_000772 16585217 NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_provenance.
- NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_assertion evidence source_evidence_literature NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_provenance.
- NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_assertion description "[Our group has documented the promise of radiolabeled anti-CD45 monoclonal antibodies (Ab) administered in the setting of allogeneic HCT for AML, but toxicity remains high, and cure rates are only 25% to 30% for relapsed AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP661115.RAJfjyf0s2XbQ2JQpI-DL0WNRMZHB4TseeKd7HXUFc-zU130_provenance.